文本框: RETROSPECTIVE STUDY OF USING INHALED GLUCOSE CORTICOSTEROID IN ASTHMATIC CHILDREN Shao J, Zhao J-Q, Xia Z-W, Li Y-Z, Yu S-C Pediatric Department, Ruijin Hospital, Shanghai Second Medical University, China Purpose: To evaluate the clinical efficacy of long term using inhaled glucose corticosteroid in asthmatic children. Methods: Collected data of 326 asthmatic children were retrospected, who were enrolled in an inhaling glucose corticosteroid (GCS) program during the 1/2 to 3-year periods. All patients were prescribed inhaled BUD or BDP according to the severity of asthma. Evaluating the frequency of nocturnal symptoms, emergency cases because of acute exacerbation, hospitalization , and amount of use β2-agonist in the previous 1/2~1 years. Results: In the group of >3 years, the follow-up survey rate was only 1.5%, group ~3 years was 28.4%, and group ~2 years and 1/2~1year were 75.3% and 88.2% respectively. 3 of 4 cases in the group of > 3 years were withdrawal of inhaled GCS, one case was using low maintenance dose. In the previous 12 month, the frequency of nocturnal symptoms, emergency cases because of acute exacerbation, hospitalization were all zero, and days of using β2-agonist was decreased from 11.6±3.7 day/month 3 years ago to 0.145±1.9 day/month currently. In the group of 2~3 years, 28 of 42 cases were withdrawal of inhaled GCS, 14 cases were using low maintenance dose. In the previous 12 month, the frequency of nocturnal symptoms, emergency cases because of acute exacerbation, hospitalization were 4.8%, 2.3% and 0 respectively, and days of using β2-agonist was decreased from 9.8±3.1 day/month before treatment to 0.56±1.6 day/month currently (9.8±3.1 VS 0.56±1.6, p<0.01). In the previous 12 month, the group of 1~2 years, 57 of 123 cases have been using low maintenance dose more 3 month, the rate of short term using systemic GCS nearly 5%, the frequency of nocturnal symptoms, emergency cases because of acute exacerbation, hospitalization were 12.2%, 6.5% and 0 respectively, and days of using β2-agonist was decreased from 5.4±2.3 day/month 3 years ago to 0.45±0.9day/month currently(5.4±2.3 VS 0.45±0.9,p<0.01). Group of 1/2 ~1 year, in the previous half year, 32 of 107 cases have been using low maintenance dose more 3 month, the rate of short term using systemic GCS nearly 5~8%, the frequency of nocturnal symptoms, emergency cases because of acute exacerbation, hospitalization were 18.7%,15.9% and 8 respectively, and days of using β2-agonist was decreased from 4.7±2.5 day/month 3 years ago to 1.27±1.1 day/month currently (4.7±2.5 VS 1.27±1.1,p<0.01). Group of 1/2 year. The frequency of nocturnal symptoms, emergency cases because of acute exacerbation, hospitalization were 28.0%, 26.0% and 6 respectively. FEV1% of all four groups had significant difference compared between before and after treatment (p<0.01). Conclusion Long term inhaled GCS could decrease asthmatic children the frequency of the frequency of nocturnal symptoms, emergency cases because of acute exacerbation, hospitalization, and amount of use β2-agonist, greatly improve patients prognosis and life quality. 0723